Last Updated on December 31, 2023 by The Health Master
The World Health Organization (WHO) has updated its living guidelines on C-19 therapeutics to include a conditional recommendation on molnupiravir, a new antiviral medicine. The recommendation is based on new data from six randomised controlled trials involving 4,796 patients. This is the largest dataset on this drug so far, WHO said in a statement.
In a statement released today, WHO said that this is the first oral anti-viral drug to be included in the treatment guidelines for C-19. As this is a new medicine, there is little safety data. WHO recommends active monitoring for drug safety, along with other strategies, to mitigate potential harms.
Because of these concerns and data gaps, molnupiravir should be provided only to non-severe C-19 patients with the highest risk of hospitalisation. These are typically people who have not received a C-19 vaccination, older people, people with immunodeficiencies and people living with chronic diseases, it said.
Children, and pregnant and breastfeeding women should not be given the drug. People who take molnupiravir should have a contraceptive plan, and health systems should ensure access to pregnancy testing and contraceptives at the point of care, the statement further mentioned.
Along with a recommendation on molnupiravir, this ninth update of WHO’s living guideline on therapeutics includes an update on casirivimab-imdevimab, a monoclonal antibody cocktail.
Based on evidence that this combination of drugs is ineffective against the Omicron variant of concern, WHO now recommends that it is only given when the infection is caused by another variant.
Molnupiravir is not widely available but steps have been taken towards increasing access, including the signing of a voluntary licensing agreement. The Access to C-19 Tools Accelerator (ACT-A) is making a limited supply available to countries with access constraints, added the statement.
WHO has also invited manufacturers to submit their products for prequalification, with a number of manufacturers of molnupiravir going through assessment now. WHO evaluates the quality, safety and efficacy of medical products for the United Nations (UN) and other large suppliers to Low- and Middle-Income Countries (LMICs), the statement concluded.
Govt listed 213 drugs for which procurement agencies could not find local manufacturers
USFDA gives nod to Lupin for Sevelamer Hydrochloride Tablets, 800 mg
USFDA declines to approve Gilead’s HIV drug on this concern
Why these Pharma Companies are realigning their India operations
USFDA approves this drug for bone marrow cancer treatment
NDPS Exporters and Importers to register with ICEGATE portal: CBN
USFDA gives nod to Unichem Laboratories for Divalproex Sodium
20 projects worth Rs. 840 crore for PLI scheme for Bulk drugs
Drug recall: Aurobindo, Sun Pharma recall these products
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
